Lumpiness after GOURI — why it happens and how to avoid it
When something became palpable decides what it is. Within two weeks and after two weeks have different causes and different responses. GOURI's own dataset is thin, so the numbers here come from injectables in general, labelled as such.
The short answer
Anything palpable within two weeks is usually a non-inflammatory lump of product pooled in one plane, and it is neither red nor tender. Something appearing after two weeks — most often three to four months after injection — red and tender, is a delayed reaction of a different kind. No nodule reports were found for GOURI, but with a denominator of 33 that means an incidence cannot be calculated, not that nodules are rare. And because polycaprolactone is not dissolved by hyaluronidase, the response runs time, medication, then physical removal.
Four routes
1. Pooling in one plane (early, non-inflammatory)
The commonest. Product that does not distribute evenly becomes palpable. On ultrasound, all 27 patients in one series of non-inflammatory nodules had the nodule within the fascial layer — that is, a question of depth rather than of lumps forming in the skin. Characteristically neither red nor painful.
2. Delayed inflammatory reaction (after two weeks)
A quiet area suddenly swells and hardens weeks or months later. The peak is three to four months after injection, and one consensus paper reported up to 71% of delayed reactions occurring between September and December. Infection, dental work and systemic inflammation are the proposed triggers — in culture-negative persistent nodules re-examined by fluorescence in situ hybridisation, bacteria were detected in 7 of 8 patients.
3. Area and skin thickness
Thin, mobile areas such as under the eye are likelier to show something. A different class, but instructive: a 42-year-old woman developed a firm, non-inflammatory nodule three weeks after a PDLLA product under the eye, reported in the literature.
4. Handling — the variable you can actually change
The same material behaves differently depending on preparation and technique. PLLA is the clearest example: nodule rates fell from 17.2% (2009 registration trial, 20/116) to 1.0% (2023, 1/97), and what changed was not the product but the reconstitution volume (5 mL to 9 mL). In one randomised comparison (150 subjects) it was 1.3% at 10–12 mL versus 8% with the standard protocol. Liquid PCL does not involve dilution in the same sense, but the lesson — handling over material — carries across.
Sorting by timing
| Timing | Nature | Accompanying signs |
|---|---|---|
| Days 0–3 | Mixed with swelling and bruising | Not red or tender. Too early to judge anything |
| Day 3 – week 2 | Non-inflammatory lump | Palpable but not red or tender — usually a plane issue |
| After week 2 – months | Delayed reaction | Redness, warmth, tenderness and swelling together change the meaning |
| Months 3–4 | Peak of delayed reactions | Quiet, then swollen and firm again |
Timing does not separate them perfectly, which is why we ask both “what day is it” and “is it red or sore”.
Incidence figures — but none of them are GOURI's
| Material | Data and denominator | Nodules |
|---|---|---|
| GOURI (liquid PCL) | 33 human subjects published | No reports found — incidence cannot be calculated |
| Microsphere PCL | 780 patients, 1,111 treatments, 3 years | Zero (the same study reported persistent oedema 4.5%, bruising 2.7%, transient lump 0.45%) |
| Hyaluronic acid filler | 2,139 patients, single centre | 7 delayed nodules = 0.33% |
| HA dermal-injection type | 131 patients, prospective single arm | 1 = 0.8%, at day 122 |
| PLLA | FDA trials, 116 / 97 subjects | 17.2% → 1.0% (dilution changed) |
| CaHA (dorsal hands) | 112 subjects | 7 = 6.2% |
The first row is the important one. GOURI is not a product without nodules; it is a product without enough human data to state a rate. No number is not zero per cent.
Prevention — what is supported, and what is only habit
| Measure | Status |
|---|---|
| Adequate dilution (PLLA) | Established — 17.2% → 1.0% |
| Even, superficial distribution | Reasonable — consistent with all 27 early nodules sitting in the fascial layer |
| Avoiding dental work for 2 weeks | Direction is reasonable, but we found no trial or cohort validating “two weeks” |
| Prophylactic antibiotics | Not recommended in any of the five major consensus papers |
| Enhanced aseptic technique | No clinical comparison showing it reduces delayed nodules (only in vitro work and practitioner surveys) |
| Post-treatment massage | Recommendations differ by product, and we found no data comparing massage for liquid PCL |
The most reliable preventive measures are unglamorous: not layering irreversible materials in the same area, and not injecting areas without data. The manufacturer's official FAQ recommends the face only and describes hand and neck data as “being collected”.
If it happens — the order of response
- Sort by timing and signs first. What day, red or tender, one side only.
- Within two weeks and non-inflammatory: observe. Most resolve — in five-year follow-up of hyaluronic acid filler adverse events, 90% were mild and required no intervention.
- With inflammatory signs, consider infection first. Because bacteria have been found even in culture-negative nodules, consensus papers favour a two-week course of a macrolide or tetracycline and reassessment.
- Intralesional steroid dosing has no standard. Recommendations range from triamcinolone 10 mg/mL to stepwise escalation. In a practice survey (334 respondents) 67% used combination therapy, but the commonest combination accounted for only 14.7%.
- If it persists, remove it physically — 21G needle aspiration or a small incision. Because polycaprolactone and polylactide are not dissolved by hyaluronidase, this is what remains.
Most improve. Hyaluronic acid granulomas are described as resolving within about a year without treatment, and conservative management of polylactide nodules has been reported to resolve 85–95% or more across studies — though the review's authors warned that the variance is wide enough that percentage estimates should be avoided.
Call without waiting if: swelling comes with redness, warmth and tenderness; pain worsens on one side only; skin becomes mottled or darker; or a new firm area appears more than two weeks after treatment. The last one is not the kind of thing that resolves with patience.
Nodules in general — rates by class, drug doses, resolution — are covered in if you can feel a nodule after treatment.
How Miso Clinic decides
- We show irreversibility and this table before treatment. That there is no dissolving agent is the largest single fact in the decision.
- We do not layer onto areas that already contain irreversible material.
- We do not treat areas without data — under the eye, neck, dorsal hands.
- We set the contact threshold by timing. Two weeks is the line; anything new at three to four months must be seen.
- We do not use prophylactic antibiotics as routine. No major consensus paper recommends it.
Items to check before choosing a clinic: seven things to check. General cautions: before you have GOURI.
Summary
Established
- Early non-inflammatory nodules: 27 of 27 within the fascial layer
- Delayed reactions peak three to four months after injection
- PLLA nodules 17.2% → 1.0%; what changed was dilution
- Bacteria found in 7 of 8 culture-negative nodules
- 90% of adverse events were mild; granulomas usually resolve within a year
Not established
- GOURI's nodule rate — 33 subjects is not a denominator
- The “two weeks” in dental-work avoidance
- Benefit of prophylactic antibiotics or enhanced asepsis
- Massage or injection depth compared for liquid PCL
- Randomised trials of nodule treatment generally
Frequently asked questions
I can feel something a few days after GOURI. Is it a complication?
If it is within two weeks and neither red nor tender, it is usually product pooled in one plane. On ultrasound all 27 patients in one early-nodule series had the nodule within the fascial layer. If redness, warmth and tenderness are present, or one side worsens, contact the clinic rather than waiting.
Is GOURI a product that does not cause nodules?
That cannot be said. No reports were found, but with only 33 published human subjects an incidence cannot be calculated. 'No number' and 'zero per cent' are different.
Can it be dissolved away?
Polycaprolactone is not hyaluronic acid, so hyaluronidase does not dissolve it. The response is observation, antibiotics where there are inflammatory signs, intralesional steroid, and if it persists, 21G aspiration or a small incision.
It swelled and hardened suddenly months later.
Delayed reactions peak three to four months after injection. Infection, dental work and systemic inflammation are the proposed triggers, and bacteria were found in 7 of 8 culture-negative nodules in one study. This situation needs to be seen rather than watched.
Should I massage the area afterwards?
We found no data comparing massage for liquid-form PCL, and recommendations differ by product and class. We prefer not to state unverified instructions as rules, and give area-specific guidance in consultation.
Should I take antibiotics as a precaution?
None of the five major consensus papers recommends prophylactic antibiotics, and we do not use them routinely.
Is the under-eye area safe?
The manufacturer's FAQ recommends facial use, but thin, mobile areas such as under the eye are where something is likeliest to be palpable. In a different class, a 42-year-old woman developed a firm, non-inflammatory nodule three weeks after a PDLLA injection under the eye. We do not treat this area.
If a nodule forms, will it eventually go away?
Most improve. Hyaluronic acid granulomas are described as resolving within about a year without treatment, and conservative management of polylactide nodules has been reported to resolve 85-95% or more across studies. The review's authors warned that the variance is wide enough that percentage predictions should be avoided.
Read next
Product page
The product itself is set out here. GOURI: liquid polycaprolactone as a collagen stimulator
Who wrote this
Written and reviewed by Lee Chi-Hak, MD, medical director of Miso Clinic in Daegu, South Korea. Every study cited above is given together with its design, its size and the limitations the authors themselves recorded, and where we could not find data, we have said that we could not find any.
| Medical director | Lee Chi-Hak, MD |
|---|---|
| Address | 4F Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu, South Korea · Exit 1, Kyungpook National University Hospital Station |
| Phone | +82-53-428-2700 |
| Hours | Weekdays 11:00–19:00 (lunch 13:00–14:00) / Saturday 10:00–16:00 (no lunch break) / Closed Sundays and public holidays |
| Columns | All clinical columns |
| Reference library | All booster and device references |
References
- Location of early non-inflammatory nodules — Schelke LW et al., Dermatologic Surgery 2023;49(6):588. 27 patients examined with 18 MHz ultrasound; the nodule lay within the fascial layer in all of them.
- Definition and timing of delayed nodules — Convery C, Davies E, Murray G, Walker L, J Clin Aesthet Dermatol 2021;14(7):E59 (defined as at least two weeks after injection; granuloma incidence 0.02–0.4%). The three-to-four-month peak and up to 71% between September and December: Alizadeh N, Baranska-Rybak W, Lajo-Plaza JV, Walker L, Dermatology and Therapy 2024.
- Hyaluronic acid filler nodules — 7 delayed nodules (0.33%) among 2,139 patients, single centre. Dermal-injection type: Niforos F et al., Clin Cosmet Investig Dermatol 2019, prospective single arm, 131 patients, 1 event at day 122 (0.8%).
- Microsphere PCL — Lin SL, Christen MO, J Cosmet Dermatol 2020;19(8):1907. 780 patients, 1,111 treatments, three years: zero nodules, granulomas, infections or intravascular events; persistent oedema 4.5%, bruising 2.7%, transient lump 0.45%.
- PLLA nodules and dilution — FDA premarket approval summaries P030050/S002 (2009, 20/116 = 17.2%) and P030050/S039 (2023, 1/97 = 1.0%). The randomised dilution comparison (150 subjects, 1.3% at 10–12 mL versus 8% with the standard protocol) is Palm et al.'s data as summarised by Flores Rodríguez JC et al., Cureus 2026;18(6):e110742.
- CaHA — Amiri M et al., J Clin Med 2024;13(6):1686; 7 of 112 in dorsal hands (6.2%).
- Bacteria in culture-negative nodules — fluorescence in situ hybridisation re-examination, 7 of 8 patients.
- Resolution rates and practice patterns — granulomas usually resolve within a year; conservative management of polylactide nodules resolved 85–95% or more across studies, though the authors warned against percentage estimates given the variance. Heterogeneity of treatment: Shalmon D et al., Clin Cosmet Investig Dermatol 2020;13:345 (334 respondents, 67% combination therapy, commonest combination 14.7%). The 90%-mild figure comes from five-year follow-up data.
- PDLLA under-eye nodule case — Seo SB, Wan J, Yi KH, J Cosmet Dermatol 2025;24(1):e16575.
- GOURI — 33 human subjects in total (Ponzo M et al., PRS Global Open 2025;13(11), PMID 41210393, plus three cases); no nodule reports found, but 33 is not a denominator. The manufacturer's official FAQ recommends facial use.
Everything in this column is general information and does not replace medical diagnosis or treatment. Effects and side effects vary with individual skin condition, age and underlying illness, and the same result is not guaranteed for everyone. Any decision to proceed should be made in an in-person consultation with a physician.
← Clinical columns · Reference library · Miso Clinic home
한국어 · English